Provided by Tiger Trade Technology Pte. Ltd.

Lyell Immunopharma, Inc.

12.63
+0.66005.51%
Post-market: 12.630.00000.00%17:01 EDT
Volume:152.49K
Turnover:1.92M
Market Cap:294.37M
PE:-0.97
High:13.02
Open:11.88
Low:11.66
Close:11.97
52wk High:45.00
52wk Low:8.46
Shares:23.31M
Float Shares:14.16M
Volume Ratio:0.77
T/O Rate:1.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-13.0558
EPS(LYR):-16.0562
ROE:-80.76%
ROA:-29.87%
PB:1.08
PE(LYR):-0.79

Loading ...

Lyell Immunopharma initial beneficial ownership filing names Innovative Cellular Therapeutics Holdings as 10% owner

Reuters
·
Jun 19

Lyell Immunopharma Shareholders Back Governance at 2026 Meeting

TIPRANKS
·
Jun 16

Lyell Immunopharma shareholders approved auditor Ernst & Young for 2026 fiscal year

Reuters
·
Jun 16

Lyell Immunopharma Price Target Maintained With a $44.00/Share by Needham

Dow Jones
·
Jun 15

BRIEF-Lyell Immunopharma Shows Updated Safety Data For Ronde-Cel In Patients With Large B-Cell Lymphoma

Reuters
·
Jun 13

Lyell Immunopharma - Pinacle Pivotal Trial Data Update Expected H2 2026; Bla Submission Planned H2 2027

THOMSON REUTERS
·
Jun 13

Lyell Immunopharma - Ronde-Cel Treated Over 100 Patients in 2L and 3L+ Lbcl With 97% Manufacturing Success Rate

THOMSON REUTERS
·
Jun 13

Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients With Large B-Cell Lymphoma at European Hematology Association 2026 Congress

THOMSON REUTERS
·
Jun 13

Lyell Immunopharma - No Grade 3 or Higher Crs and Low Rates of Grade 3 or Higher Icans Reported

THOMSON REUTERS
·
Jun 13

Lyell Immunopharma says ronde-cel Phase 1/2 study in LBCL shows no grade 3+ CRS

Reuters
·
Jun 13

Lyell Immunopharma Price Target Maintained With a $44.00/Share by Needham

Dow Jones
·
Jun 08

Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Lyell Immunopharma (LYEL)

TIPRANKS
·
Jun 08

Lyell Immunopharma Provides Update on Safety Profile of Lyl273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion

THOMSON REUTERS
·
Jun 08

Lyell Immunopharma - No Difference in GCC Car T-Cell Expansion With or Without Gi Prophylaxis

THOMSON REUTERS
·
Jun 08

Lyell Immunopharma - Maximum Tolerated Dose Not yet Determined

THOMSON REUTERS
·
Jun 08

Lyell Immunopharma - Additional Phase 1 Data and FDA Meeting Expected in Second Half of 2026

THOMSON REUTERS
·
Jun 08

Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion

GlobeNewswire
·
Jun 08

Lyell Immunopharma presents Phase 1/2 safety, translational data for ronde-cel in relapsed/refractory large B-cell lymphoma at EHA 2026

Reuters
·
Jun 05

Analysts Conflicted on These Healthcare Names: Arvinas Holding Company (ARVN), Lyell Immunopharma (LYEL) and Relay Therapeutics (RLAY)

TIPRANKS
·
Jun 03

Lyell Immunopharma Price Target Maintained With a $45.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 03